Literature DB >> 12957356

4-Hydroxycoumarin disorganizes the actin cytoskeleton in B16-F10 melanoma cells but not in B82 fibroblasts, decreasing their adhesion to extracellular matrix proteins and motility.

Marco Antonio Velasco-Velázquez1, José Agramonte-Hevia, Diana Barrera, Alejandro Jiménez-Orozco, María Juana García-Mondragón, Nicandro Mendoza-Patiño, Abraham Landa, Juan Mandoki.   

Abstract

This study determined the in vitro effects of 4-hydroxycoumarin (4-HC) employing the melanoma cell line B16-F10 and the non-malignant fibroblastic cell line B82. 4-HC disorganized the actin cytoskeleton in B16-F10 cells, but not in B82 fibroblasts. Cytoskeletal disorganization correlated with reductions in cell adhesion to four extracellular matrix proteins and inhibition of random motility. 4-HC did not modify cell viability or actin expression, but decreased tyrosine phosphorylation of several proteins in melanoma cells. Because adhesion of tumor cells to extracellular matrix is required during the metastatic process, 4-HC might be useful as an adjuvant therapy for melanoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957356     DOI: 10.1016/s0304-3835(03)00333-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

Review 1.  Effects of psoralens as anti-tumoral agents in breast cancer cells.

Authors:  Maria Luisa Panno; Francesca Giordano
Journal:  World J Clin Oncol       Date:  2014-08-10

2.  Exploring the anti-proliferative activity of Pelargonium sidoides DC with in silico target identification and network pharmacology.

Authors:  A S P Pereira; M J Bester; Z Apostolides
Journal:  Mol Divers       Date:  2017-09-18       Impact factor: 2.943

3.  Esculin and its oligomer fractions inhibit adhesion and migration of U87 glioblastoma cells and in vitro angiogenesis.

Authors:  Imen Mokdad-Bzeouich; Hervé Kovacic; Kamel Ghedira; Latifa Chebil; Mohamed Ghoul; Leila Chekir-Ghedira; José Luis
Journal:  Tumour Biol       Date:  2015-10-12

4.  Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia.

Authors:  Grzegorz S Nowakowski; James D Hoyer; Tait D Shanafelt; Clive S Zent; Timothy G Call; Nancy D Bone; Betsy Laplant; Gordon W Dewald; Renee C Tschumper; Diane F Jelinek; Thomas E Witzig; Neil E Kay
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

5.  Mannich bases of hydroxycoumarins: synthesis, DFT/QTAIM computational study and assessment of biological activity.

Authors:  J Sergio Durand-Niconoff; Erik Ortiz-Blanco; Gabriela Sosa-Ortiz; José L Olivares-Romero; Enrique Juárez-Aguilar; Eva Luz Montoya-Hernández; Cynthia Fernández-Pomares; Ricardo Tovar-Miranda; María Eugenia Castro; Francisco J Melendez; Tomás Guerrero
Journal:  RSC Adv       Date:  2021-09-22       Impact factor: 4.036

6.  Structure-activity relationships of 3,3'-phenylmethylene-bis-4-hydroxycoumarins: selective and potent inhibitors of gram-positive bacteria.

Authors:  Kanokporn Petnapapun; Warinthorn Chavasiri; Pornthep Sompornpisut
Journal:  ScientificWorldJournal       Date:  2013-12-29

7.  Nanodiamonds coupled with 5,7-dimethoxycoumarin, a plant bioactive metabolite, interfere with the mitotic process in B16F10 cells altering the actin organization.

Authors:  Angelo Gismondi; Valentina Nanni; Giacomo Reina; Silvia Orlanducci; Maria Letizia Terranova; Antonella Canini
Journal:  Int J Nanomedicine       Date:  2016-02-03

8.  Impairment of the activin A autocrine loop by lopinavir reduces self-renewal of distinct human adipose progenitors.

Authors:  Christophe Ravaud; Martin Paré; Stéphane Azoulay; Christian Dani; Annie Ladoux
Journal:  Sci Rep       Date:  2017-06-07       Impact factor: 4.379

9.  Reduced paxillin expression contributes to the antimetastatic effect of 4-hydroxycoumarin on B16-F10 melanoma cells.

Authors:  Marco A Velasco-Velázquez; Nohemí Salinas-Jazmín; Nicandro Mendoza-Patiño; Juan J Mandoki
Journal:  Cancer Cell Int       Date:  2008-05-20       Impact factor: 5.722

10.  Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells.

Authors:  Charmina Aguirre-Alvarado; Aldo Segura-Cabrera; Inés Velázquez-Quesada; Miguel A Hernández-Esquivel; Carlos A García-Pérez; Sandra L Guerrero-Rodríguez; Angel J Ruiz-Moreno; Andrea Rodríguez-Moreno; Sonia M Pérez-Tapia; Marco A Velasco-Velázquez
Journal:  Oncotarget       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.